Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
AIM Real-world data inform the outcome comparisons and help the development of new therapeutic strategies. To this end, we aimed to describe the full characteristics and outcomes in the Epidemiological Strategy and Medical Economics (ESME) cohort, a large national contemporary observational database of patients with metastatic breast cancer (MBC). METHODS Women aged ≥18 years with newly diagnosed MBC and who initiated MBC treatment between January 2008 and December 2016 in one of the 18 French Comprehensive Cancer Centers (N = 22,109) were included. We assessed the full patients' characteristics, first-line treatments, overall survival (OS) and first-line progression-free survival, as well as updated prognostic factors in the whole cohort and among the 3 major subtypes: hormone receptor positive and HER2-negative (HR+/HER2-, n = 13,656), HER2-positive (HER2+, n = 4017) and triple-negative (n = 2963) tumours. RESULTS The median OS of the whole cohort was 39.5 months (95% confidence interval [CI], 38.7-40.3). Five-year OS was 33.8%. OS differed significantly between the 3 subtypes (p < 0.0001) with a median OS of 43.3 (95% CI, 42.5-44.5) in HR+/HER2-; 50.1 (95% CI, 47.6-53.1) in HER2+; and 14.8 months (95% CI, 14.1-15.5) in triple-negative subgroups, respectively. Beyond performance status, the following variables had a constant significant negative prognostic impact on OS in the whole cohort and among subtypes: older age at diagnosis of metastases (except for the triple-negative subtype), metastasis-free interval between 6 and 24 months, presence of visceral metastases and number of metastatic sites ≥ 3. CONCLUSIONS The ESME program represents a unique large-scale real-life cohort on MBC. This study highlights important situations of high medical need within MBC patients. DATABASE REGISTRATION: clinicaltrials.gov Identifier NCT032753.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Self-citation
Research works printed but not linked: 23
- Cardoso, 2018, 4th ESO–ESMO International Consensus guidelines for advanced breast cancer (ABC 4)†, Ann Oncol, 29, 1634, 10.1093/annonc/mdy192 · DOI · Paper page
- Ferlay, 2018, Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018, Eur J Canc, 103, 356, 10.1016/j.ejca.2018.07.005 · DOI · Paper page
- Gobbini, 2018, Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort, Eur J Canc, 96, 17, 10.1016/j.ejca.2018.03.015 · DOI · Paper page
- von Minckwitz, 2017, Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer, N Engl J Med, 377, 122, 10.1056/NEJMoa1703643 · DOI · Paper page
- Skovlund, 2018, The use of real-world data in cancer drug development, Eur J Canc, 101, 69, 10.1016/j.ejca.2018.06.036 · DOI
- Singh, 2018, Real world big data for clinical research and drug development, Drug Discov Today, 23, 652, 10.1016/j.drudis.2017.12.002 · DOI
- Schurman, 2019, The framework for FDA's real-world evidence program, Appl Clin Trials, 28, 15
- Khozin, 2017, Real-world data for clinical evidence generation in oncology, J Natl Cancer Inst, 109, 10.1093/jnci/djx187 · DOI · Paper page
- Jacquet, 1990, Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients, Eur J Cancer Oxf Engl, 95, 93, 10.1016/j.ejca.2018.03.013 · DOI
- Pérol, 2019, The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME), BMJ Open, 9, 10.1136/bmjopen-2018-023568 · doi:10.1136/bmjopen-2018-023568
- Wolff, 2007, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J Clin Oncol Off J Am Soc Clin Oncol, 25, 118, 10.1200/JCO.2006.09.2775 · DOI · Paper page
- Wolff, 2014, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, Arch Pathol Lab Med, 138, 241, 10.5858/arpa.2013-0953-SA · DOI · Paper page
- Wolff, 2018, Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/College of American pathologists clinical practice guideline focused update, J Clin Oncol, 36, 2105, 10.1200/JCO.2018.77.8738 · DOI · Paper page
- Caswell-Jin, 2018, Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review, JNCI Cancer Spectr, 2, 10.1093/jncics/pky062 · DOI · Paper page
- Krop, 2017, Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial, Lancet Oncol, 18, 743, 10.1016/S1470-2045(17)30313-3 · DOI · Paper page
- Diéras, 2017, Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial, Lancet Oncol, 18, 732, 10.1016/S1470-2045(17)30312-1 · DOI · Paper page
- Yardley, 2014, Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer, Breast Canc Res Treat, 145, 725, 10.1007/s10549-014-2916-8 · DOI
- Loibl, 2017, HER2-positive breast cancer, Lancet, 389, 2415, 10.1016/S0140-6736(16)32417-5 · DOI · Paper page
- Largillier, 2008, Prognostic factors in 1038 women with metastatic breast cancer, Ann Oncol, 19, 10.1093/annonc/mdn424 · DOI · Paper page
- Lobbezoo, 2015, Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?, Br J Canc, 112, 1445, 10.1038/bjc.2015.127 · DOI · Paper page
- Ruiterkamp, 2009, Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis, Eur J Surg Oncol, 35, 1146, 10.1016/j.ejso.2009.03.012 · DOI · Paper page
- Hartkopf, 2018, Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – data from the German PRAEGNANT breast cancer registry, Breast, 37, 42, 10.1016/j.breast.2017.10.002 · DOI
- Saux, 2019, Assessment of the efficacy of successive endocrine therapies in hormone receptor–positive and HER2-negative metastatic breast cancer: a real-life multicentre national study, Eur J Canc, 118, 131, 10.1016/j.ejca.2019.06.014 · DOI
Cited by
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“Survival is strongly related to breast cancer subtype, with the major advances seen in human epidermal growth factor receptor 2 (HER2)-positive ABC.(5-9) ABC is a treatable disease with several available therapies and many others in development.”
Background
Metadata
- Authors
- Deluche, E., Antoine, A., Bachelot, T., Lardy-Cleaud, A., Dieras, V., Brain, E., Debled, M., Jacot, W., Mouret-Reynier, M. A., Goncalves, A., Dalenc, F., Patsouris, A., Ferrero, J. M., Levy, C., Lorgis, V., Vanlemmens, L., Lefeuvre-Plesse, C., Mathoulin-Pelissier, S., Petit, T., Uwer, L., Jouannaud, C., Leheurteur, M., Lacroix-Triki, M., Courtinard, C., Perol, D., Robain, M., & Delaloge, S.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 129
- Pages
- 60-70
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W3009223368
- Cited by
- 186
- References
- 2
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- Roche
- AstraZeneca
- Pfizer
- Les Laboratories Pierre Fabre
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.